Core Insights - Instil Bio, Inc. announced preliminary efficacy and safety data for '2510 in a Phase 1 study for previously treated squamous non-small cell lung cancer (sq-NSCLC) patients, highlighting an objective response rate (ORR) of 35.3% [1][2] Company Overview - Instil Bio is a clinical-stage biopharmaceutical company focused on developing novel therapies, with its lead asset being AXN-2510, a PD-L1xVEGF bispecific antibody aimed at treating multiple solid tumors [3] Study Details - The Phase 1 study involved 23 patients with sq-NSCLC who had previously failed PD-(L)1 inhibitor and platinum-doublet chemotherapy, with 6 patients having prior VEGF-directed therapy [2] - Patients were treated with '2510 at varying doses, primarily at 20 mg/kg Q2W, and the majority of responses were observed in patients with negative and low PD-L1 TPS scores [2] - The study reported that '2510 was generally safe and well tolerated, with manageable low-grade infusion reactions and two Grade 3 VEGF-related adverse events [2] Efficacy and Safety - The ORR of 35.3% was noted in the 17 efficacy-evaluable patients, with ongoing treatment for most patients and opportunities for further tumor assessments [2] - The promising preliminary data for '2510 in sq-NSCLC patients who have failed prior therapies is considered favorable compared to other molecules in the PD-(L)1xVEGF bispecific class [3]